Pharmaceutical companies Eli Lilly and Novo Nordisk are conducting research to extend the use of their weight-loss drugs to children. Eli Lilly is preparing to test its diabetes medication Mounjaro in children diagnosed with obesity who are six years old and above, while Novo Nordisk is examining the use of Saxenda, a medication related to its diabetes drugs Ozempic and Wegovy, in the same demographic.
The move by these companies to consider children in their trials comes amidst a broader recognition of the prevalence of obesity in younger populations. Eli Lilly has already begun studies involving adolescents aged 12 and up.
As the pharmaceutical industry continues to explore solutions for obesity, these companies have experienced growth in their stock valuations. The exploration of pediatric applications for these medications may contribute to ongoing trends in the market as the companies respond to a public health need.
